| 1 | CYPHB1, CYPHB2, NR3C2, HSD11B2, SCNN1B, SCNN1G, PSALD, PHA2C, WNK1, PHA2B, WNK4, DIDAN, PPARG, MTHHH, MT-TI
|
| The genetic dissection of essential hypertension.
|
| Cowley AW Jr.
|
| Nat Rev Genet 7(11):829-40. Epub 2006 Oct 10. Review. 2006
|
| 2 | DIDAN, PPP1R3A
|
| Digenic inheritance of severe insulin resistance in a human pedigree.
|
| Savage DB, Agostini M, Barroso I, Gurnell M, Luan J, Meirhaeghe A, Harding AH, Ihrke G, Rajanayagam O, Soos MA, George S, Berger D, Thomas EL, Bell JD, Meeran K, Ross RJ, Vidal-Puig A, Wareham NJ, O'Rahilly S, Chatterjee VK, Schafer AJ.
|
| Nat Genet 31(4):379-84. 2002
|
| 3 | EGR1, DIDAN
|
| Early growth response factor-1 is a critical transcriptional mediator of peroxisome proliferator-activated receptor-gamma 1 gene expression in human aortic smooth muscle cells.
|
| Fu M, Zhang J, Lin Y, Zhu X, Ehrengruber MU, Chen YE.
|
| J Biol Chem 277(30):26808-14. 2002
|
| 4 | DIDAN
|
| Opposite association of two PPARG variants with cancer: overrepresentation of H449H in endometrial carcinoma cases and underrepresentation of P12A in renal cell carcinoma cases.
|
| Smith WM, Zhou XP, Kurose K, Gao X, Latif F, Kroll T, Sugano K, Cannistra SA, Clinton SK, Maher ER, Prior TW, Eng C.
|
| Hum Genet 109(2):146-51. 2001
|
| 5 | CAPN10, NIDDM20, DIDAN
|
| Genetic determinants of type 2 diabetes mellitus.
|
| Busch C, Hegele R.
|
| Clin Genet 60(4):243-54. 2001
|
| 6 | DIDAN
|
| Identification of a novel peroxisome proliferator-activated receptor (PPAR) gamma promoter in man and transactivation by the nuclear receptor RORalpha1.
|
| Sundvold H, Lien S.
|
| Biochem Biophys Res Commun 287(2):383-90. 2001
|
| 7 | DIDAN
|
| The identification and characterization of a STAT 1 binding site in the PPARgamma2 promoter.
|
| Hogan JC, Stephens JM.
|
| Biochem Biophys Res Commun 287(2):484-92. 2001
|
| 8 | DIDAN
|
| Over-representation of PPARgamma sequence variants in sporadic cases of glioblastoma multiforme: preliminary evidence for common low penetrance modifiers for brain tumour risk in the general population.
|
| Zhou XP, Smith WM, Gimm O, Mueller E, Gao X, Sarraf P, Prior TW, Plass C, von Deimling A, Black PM, Yates AJ, Eng C.
|
| J Med Genet 37(6):410-4. 2000
|
| 9 | PAX8, DIDAN
|
| PAX8-PPARgamma1 fusion in oncogene human thyroid carcinoma.
|
| Kroll TG, Sarraf P, Pecciarini L, Chen CJ, Mueller E, Spiegelman BM, Fletcher JA.
|
| Science 289(5483):1357-60. 2000
|
| 10 | DIDAN
|
| The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes.
|
| Altshuler D, Hirschhorn JN, Klannemark M, Lindgren CM, Vohl MC, Nemesh J, Lane CR, Schaffner SF, Bolk S, Brewer C, Tuomi T, Gaudet D, Hudson TJ, Daly M, Groop L, Lander ES.
|
| Nat Genet 26(1):76-80. No abstract available. 2000
|
| 11 | DIDAN
|
| The Pro12Ala polymorphism in PPAR gamma2 may confer resistance to type 2 diabetes.
|
| Hara K, Okada T, Tobe K, Yasuda K, Mori Y, Kadowaki H, Hagura R, Akanuma Y, Kimura S, Ito C, Kadowaki T.
|
| Biochem Biophys Res Commun 271(1):212-6. 2000
|
| 12 | DIDAN
|
| PPARgamma activation in human endothelial cells increases plasminogen activator inhibitor type-1 expression: PPARgamma as a potential mediator in vascular disease.
|
| Marx N, et al.
|
| Arterioscler Thromb Vasc Biol 19(3):546-51. 1999
|
| 13 | DIDAN
|
| The PPARgamma2 amino acid polymorphism Pro 12 Ala is prevalent in offspring of Type II diabetic patients and is associated to increased insulin sensitivity in a subgroup of obese subjects.
|
| Koch M, et al.
|
| Diabetologia 42(6):758-62. 1999
|
| 14 | DIDAN
|
| Pro12Ala substitution in the peroxisome proliferator-activated receptor-gamma2 is not associated with type 2 diabetes.
|
| Mancini FP, et al.
|
| Diabetes 48(7):1466-8. 1999
|
| 15 | DIDAN
|
| Homozygosity of the Pro12Ala variant of the peroxisome proliferation-activated receptor-gamma2 (PPAR-gamma2): divergent modulating effects on body mass index in obese and lean Caucasian men.
|
| Ek J, et al.
|
| Diabetologia 42(7):892-5 1999
|
| 16 | DIDAN
|
| Missense variants in the human peroxisome proliferator-activated receptor-gamma2 gene in lean and obese subjects.
|
| Hamann A, et al.
|
| Eur J Endocrinol 141(1):90-2 1999
|
| 17 | CEBPA, CEBPB, CEBPD, DIDAN
|
| PPARgamma: an essential regulator of adipogenesis and modulator of fat cell function.
|
| Lowell BB.
|
| Cell 99(3):239-42. Review. No abstract available 1999
|
| 18 | DIDAN
|
| Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension.
|
| Barroso I, Gurnell M, Crowley VE, Agostini M, Schwabe JW, Soos MA, Maslen GL, Williams TD, Lewis H, Schafer AJ, Chatterjee VK, O'Rahilly S.
|
| Nature 402(6764):880-3 1999
|
| 19 | DIDAN
|
| Loss-of-function mutations in PPAR gamma associated with human colon cancer.
|
| Sarraf P, Mueller E, Smith WM, Wright HM, Kum JB, Aaltonen LA, de la Chapelle A, Spiegelman BM, Eng C.
|
| Mol Cell 3(6):799-804. 1999
|
| 20 | DIDAN, PPARG
|
| PPAR gamma is required for placental, cardiac, and adipose tissue development.
|
| Barak Y, Nelson MC, Ong ES, Jones YZ, Ruiz-Lozano P, Chien KR, Koder A, Evans RM.
|
| Mol Cell. 4(4):585-95. 1999
|
| 21 | DIDAN, PPARG
|
| PPAR gamma mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance.
|
| Kubota N, Terauchi Y, Miki H, Tamemoto H, Yamauchi T, Komeda K, Satoh S, Nakano R, Ishii C, Sugiyama T, Eto K, Tsubamoto Y, Okuno A, Murakami K, Sekihara H, Hasegawa G, Naito M, Toyoshima Y, Tanaka S, Shiota K, Kitamura T, Fujita T, Ezaki O, Aizawa S, Kadowaki T, et al.
|
| Mol Cell. 4(4):597-609. 1999
|
| 22 | DIDAN, PPARG
|
| PPAR gamma is required for the differentiation of adipose tissue in vivo and in vitro.
|
| Rosen ED, Sarraf P, Troy AE, Bradwin G, Moore K, Milstone DS, Spiegelman BM, Mortensen RM.
|
| Mol Cell. 4(4):611-7. 1999
|
| 23 | DIDAN
|
| PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines.
|
| Jiang C, Ting AT, Seed B.
|
| Nature 391(6662):82-6. 1998
|
| 24 | DIDAN
|
| The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation.
|
| Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK.
|
| Nature 391(6662):79-82. 1998
|
| 25 | DIDAN
|
| A genetic polymorphism of the peroxisome proliferator-activated receptor gamma gene influences plasma leptin levels in obese humans.
|
| Meirhaeghe A, Fajas L, Helbecque N, Cottel D, Lebel P, Dallongeville J, Deeb S, Auwerx J, Amouyel P.
|
| Hum Mol Genet 7(3):435-40. 1998
|
| 26 | DIDAN
|
| Human peroxisome proliferator-activated receptor-gamma2. Genetic mapping, identification of a variant in the coding sequence, and exclusion as the gene responsible for lipoatrophic diabetes.
|
| Vigouroux C, et al.
|
| Diabetes 47 : 490-492. 1998
|
| 27 | DIDAN
|
| Expression of the peroxisome proliferator-activated receptor gamma (PPARgamma) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein.
|
| Ricote M, et al.
|
| Proc Natl Acad Sci U S A 95 : 7614-7619. 1998
|
| 28 | DIDAN
|
| Obesity associated with a mutation in a genetic regulator of adipocyte differentiation.
|
| Ristow M, et al.
|
| N Engl J Med 339 : 953-959. 1998
|
| 29 | DIDAN
|
| A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity.
|
| Deeb SS, et al.
|
| Nat Genet 20 : 284-287. 1998
|
| 30 | DIDAN
|
| Induction of PPARgamma1 expression in human THP-1 monocytic leukemia cells by 9-cis-retinoic acid is associated with cellular growth suppression.
|
| Zhu L, Gong B, Bisgaier CL, Aviram M, Newton RS.
|
| Biochem Biophys Res Commun 251 : 842-848. 1998
|
| 31 | AGRP, CLU, CPE, MC4R, NPY5R, NPY6R, PCSK1, POMC, DIDAN, TUB, UCP2
|
| Microsatellite marker content mapping of 12 candidate genes for obesity: assembly of seven obesity screening panels for automated genotyping.
|
| Winick JD, Friedman JM.
|
| Genome Res 8(9):985-94. 1998
|
| 32 | DIDAN
|
| Terminal differentiation of human breast cancer through PPAR gamma.
|
| Mueller E, Sarraf P, Tontonoz P, Evans RM, Martin KJ, Zhang M, Fletcher C, Singer S, Spiegelman BM.
|
| Mol Cell 1(3):465-70. 1998
|
| 33 | DIDAN
|
| The nuclear eicosanoid receptor, PPARgamma, is aberrantly expressed in colonic cancers.
|
| DuBois RN, Gupta R, Brockman J, Reddy BS, Krakow SL, Lazar MA.
|
| Carcinogenesis 19(1):49-53. 1998
|
| 34 | DIDAN
|
| Chromosomal localization and partial genomic structure of the human peroxisome proliferator activated receptor-gamma (hPPAR gamma) gene.
|
| Beamer BA, Negri C, Yen CJ, Gavrilova O, Rumberger JM, Durcan MJ, Yarnall DP, Hawkins AL, Griffin CA, Burns DK, Roth J, Reitman M, Shuldiner AR.
|
| Biochem Biophys Res Commun 233(3):756-9. 1997
|
| 35 | DIDAN
|
| The organization, promoter analysis, and expression of the human PPARgamma gene.
|
| Fajas L, Auboeuf D, Raspe E, Schoonjans K, Lefebvre AM, Saladin R, Najib J, Laville M, Fruchart JC, Deeb S, Vidal-Puig A, Flier J, Briggs MR, Staels B, Vidal H, Auwerx J.
|
| J Biol Chem 272(30):18779-89. 1997
|
| 36 | DIDAN
|
| No coding mutations are detected in the peroxisome proliferator-activated receptor-gamma gene in Japanese patients with lipoatrophic diabetes.
|
| Okazawa H, Mori H, Tamori Y, Araki S, Niki T, Masugi J, Kawanishi M, Kubota T, Shinoda H, Kasuga M.
|
| Diabetes 46(11):1904-6. 1997
|
| 37 | DIDAN
|
| Molecular scanning of the human peroxisome proliferator activated receptor gamma (hPPAR gamma) gene in diabetic Caucasians : identification of a Pro12Ala PPAR gamma 2 missense mutation.
|
| Yen CJ, Beamer BA, Negri C, Silver K, Brown KA, Yarnall DP, Burns DK, Roth J, Shuldiner AR.
|
| Biochem Biophys Res Commun 241(2):270-4. 1997
|
| 38 | PPARA, PPARD, DIDAN
|
| Peroxisome proliferator-activated receptors and retinoic acid receptors differentially control the interactions of retinoid X receptor heterodimers with ligands, coactivators, and corepressors.
|
| DiRenzo J, et al.
|
| Mol Cell Biol 17 : 2166-2176. 1997
|
| 39 | DIDAN
|
| Identification, characterization, and tissue distribution of human peroxisome proliferator-activated receptor (PPAR) isoforms PPARgamma2 versus PPARgamma1 and activation with retinoid X receptor agonists and antagonists.
|
| Mukherjee R, Jow L, Croston GE, Paterniti JR Jr.
|
| J Biol Chem 272(12):8071-6. 1997
|
| 40 | DIDAN
|
| Ligand-independent activation domain in the N terminus of peroxisome proliferator-activated receptor gamma (PPARgamma). Differential activity of PPARgamma1 and -2 isoforms and influence of insulin.
|
| Werman A, Hollenberg A, Solanes G, Bjorbaek C, Vidal-Puig AJ, Flier JS.
|
| J Biol Chem 272(32):20230-5. 1997
|
| 41 | DIDAN
|
| Molecular cloning, expression and characterization of human peroxisome proliferator activated receptors gamma1 and gamma2.
|
| Elbrecht A, et al.
|
| Biochem Biophys Res Commun 224 : 431-437. 1996
|
| 42 | DIDAN, NCOA1
|
| Cloning and identification of mouse steroid receptor coactivator-1 (mSRC-1), as a coactivator of peroxisome proliferator-activated receptor gamma.
|
| Zhu Y, et al.
|
| Gene Expr 6(3):185-95 1996
|
| 43 | DIDAN
|
| Isolation of the human peroxisome proliferator activated receptor gamma cDNA: expression in hematopoietic cells and chromosomal mapping.
|
| Greene ME, Blumberg B, McBride OW, Yi HF, Kronquist K, Kwan K, Hsieh L, Greene G, Nimer SD.
|
| Gene Expr 4(4-5):281-99. 1995
|